Questions for the pharma industry? Ask Roger Perlmutter, EVP R&D at Amgen

Hi Dr. Perlmutter,

I've been worried about the rise of antibiotic resistant bacteria. What can you tell me about the research taking place to defeat these resistant bugs.

It seems like an opportunity to make money while doing good.

Thanks,

Jerry

Dr. Perlmutter, I read in the LA Times (http://is.gd/6ehk) about how the Supreme Court is split over whether to shield drug makers from being sued if they fail to warn patients and doctors of all the risks of a prescription drug -- and if a federal agency such as the FDA regulates the product. What's your opinion?

I am very interested in the side effects from Zetia; especially if it causes weight gain, along with the drug Crestor.

Thank you.

How does collaboration work in your field, with NDA's, patents and contractual firewalls and red tapes. How do you work with vendors or partners in a positive manner to be able to achieve benificial outcomes for all stake holders without projects falling into caotic disruption. We have found that in the past lawyers can really quickly kill collaboration and hence cross company innovation.

Thanks so much for the great questions. Don't forget to include your name as you'd like us to credit you -- and your location. Thanks again -- keep the questions coming, and I'll post the video here once it's ready.

Dr Roger,
How far this new Osteoporosis drug molecule is safe as blockbuster in relation to current dronate molecules?
Thanks

Greetings,

We've seen the rough lessons in the financial markets of allowing too much consolidation, to the point that an oligopoly is established, where inidividual players can move the marketplace.

Do you feel we should be applying this lesson learned to the pharma/biotech industry and making it more difficult for large consolidations to occur (such as Roche's recent move to absorb Genentech). Do you worry that this will inhibit innovative research and expose the industry to too much concentrated risk in the hands of only a few companies?

Thanks,
Michael

Dr. Perlmutter:

The situation in Big Pharma today reminds me of the competitive threat posed by Japanese manufacturers to the US semiconductor industry during the 1980s. Back then, the industry formed a very effective consortium (Sematech) to share information and develop new products.

Do you think Amgen and other big pharma companies would ever be able to work together in a similar fashion by sharing information about failures in late-stage clinical trials as well as new strategies in early stage drug development?

I do not have a Comment but i have a question!!!!
What is the behind reasons of the financial crisis.????

Hi,

Thankyou very much for reading my little sentences. I was curious about whether the R and D cells in Pharma companies consider the chances of a collaboration with Alternative forms of medicine like Alopathy or Homeopathy? Since the breakthrough for the impasee was once biochemistry, why not these fields that I mentioned? I will be glad to hear your comments.

1) What impact with the Obama administration have on Amgen's business?

2) Under the Obama administration, what is the probability of an FOB pathway being created in the U.S. and what is Amgen's stance on FOB's?

Thanks, all, for your great questions. We picked five and Arlene put them to Roger yesterday. We're now editing and will post the video on 1112 (I'll post the link when it's available.) Apologies in advance if we did not get to your question, but I think (hope!) you'll find Perlmutter's comments compelling all the same. Thanks again, Helen

Hi all. Here's the link to the video: http://www.businessweek.com/innovate/next/archives/2008/11/five_answers_fr.html

Will you pepole help me to solve the problem related to Microbiology.
My question is that : What is the mean of Microbila load record? is it means Area monitaring? which points add in preparation of SOP.
Second : how to perform clean area validation. Is their is band in use fumigation procedure